Suzuki Yasuhiro, Ogiya Rin, Oshitanai Risa, Terao Mayako, Terada Mizuho, Morioka Toru, Tsuda Banri, Niikura Naoki, Okamura Takuho, Saito Yuki, Tokuda Yutaka
Division of Breast and Endocrine Surgery, Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan,
Int J Clin Oncol. 2014 Apr;19(2):274-9. doi: 10.1007/s10147-013-0547-4. Epub 2013 Apr 5.
To clarify the tolerance and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer.
From January 2008 through to September 2009, combined therapy with S-1 and trastuzumab was given to 7 patients with HER2-positive metastatic or recurrent breast cancer. The incidence of adverse events and the pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil in plasma were studied.
One patient had grade 3 leukopenia, and another had a grade 3 elevation of alanine aminotransferase. All other adverse events were grade 2 or lower. The combination of S-1 and trastuzumab did not cause any new adverse events. The incidence of adverse events was similar to those associated with S-1 alone. The median number of treatment cycles was 11. The pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil after treatment with S-1 plus trastuzumab did not markedly differ from those after S-1 alone.
Combined therapy with S-1 and trastuzumab did not cause any new adverse events, administration continuity was good, and the therapy was well tolerated.
明确S-1与曲妥珠单抗联合治疗人表皮生长因子受体2（HER2）阳性转移性或复发性乳腺癌患者的耐受性和药代动力学。
2008年1月至2009年9月，对7例HER2阳性转移性或复发性乳腺癌患者给予S-1与曲妥珠单抗联合治疗。研究不良事件的发生率以及血浆中替加氟、5-氟尿嘧啶和吉美嘧啶的药代动力学。
1例患者出现3级白细胞减少，另1例患者丙氨酸转氨酶升高至3级。所有其他不良事件均为2级或更低级别。S-1与曲妥珠单抗联合使用未引起任何新的不良事件。不良事件的发生率与单独使用S-1时相似。治疗周期的中位数为11个。S-1加曲妥珠单抗治疗后替加氟、5-氟尿嘧啶和吉美嘧啶的药代动力学与单独使用S-1后相比无明显差异。
S-1与曲妥珠单抗联合治疗未引起任何新的不良事件，给药连续性良好，且该治疗耐受性良好。
